| This week's sponsor is INC Research. | |  | |
Top Stories Friday, October 7, 2016 The word in cancer right now is combination, and Merck KGaA, coming in the same week it opened a new life science R&D collab center in Korea, is joining forces in the lab with Vaccinex to see if together their investigational meds can help patients with lung cancer live longer. Thursday, October 6, 2016 Philadelphia, PA-based Immunome has raised $5 million of a Series A round in April that it now said will hit $12.2 million. Friday, October 7, 2016 Newron Pharmaceuticals has tapped investors for CHF 26.1 million to see it through to data readouts on a couple of key pipeline programs. The funding extends Newron’s financial runway out beyond the completion of a Phase IIa schizophrenia trial and Phase II/III orphan CNS disease study. Friday, October 7, 2016 In the first quarter after Britain voted to leave the European Union, life sciences deals took a nosedive--and while Asia booked impressive surges in M&A activity, the U.S. also saw a drop in deals as tax inversion rules and pricing pressures kick in. Thursday, October 6, 2016 Obalon Therapeutics is making its market debut, launching an IPO of $75 million to fuel U.S. commercialization of its weight loss balloon device. Thursday, October 6, 2016 Amgen and Nuevolution pen an R&D pact, ambitious Carrick raises $95 million, Medicxi founds Kymo, and more. Thursday, October 6, 2016 Genzyme's former VP becomes Editas' CMO, SynteractHCR makes three high-profile appointments, Michael Rogers steps down as Acorda’s CFO. Plus more hirings, firings and retirings throughout the industry. | This week's sponsor is FierceBiotech. | |  | FierceBiotech Presents:
A Half Day Executive Summit
Hosted at the Royal Society of Medicine, London
R&D Challenges: A UK Perspective
Cocktail Reception to follow
27 October, 2016
Register Now! |
| | | Israel's Alcobra has received a formal FDA clinical hold letter for its Phase III test of MDX in ADHD patients after “electrophysiological neurologic findings” were found in some animal studies. Release Obesity biotech Nexus BioPharma has signed a deal with TransChem for its transition state chemistry tech for kinase inhibition. Statement Cancer and rare disease firm Idera Pharmaceuticals has priced an underwritten public offering of 25 million shares of common stock at a price of $2 apiece. Release | |
|
Resources Presented by: Covance The role of health economic data has never been more important. Presented by: Covance Leading manufacturers increasingly employ stakeholder research early in development to better identify the needs of patients and providers. Presented By: ISR Reports ISR’s Bioprocessing Market Trends and Outsourcing Dynamics: 2016-2021 report provides an overview of the current market dynamics for bioprocessing as well as an outlook on what the marketplace will look like in five years. Presented By: ISR Reports ISR’s CRO Quality Benchmarking – Phase II/III Service Providers (8th Edition) report provides a Consumer Reports-style analysis of Phase II/III CRO service quality from hundreds of users who rated 44 Phase II/III CROs across 26 critical dimensions of quality. Presented by: Patheon Can you avoid a risky trial-and-error approach to find the right path for your poorly soluble molecule by utilizing a CDMO? Download this complimentary Whitepaper to learn more! Presented by: Biotech Primer This 3-part webinar series is specifically geared toward the non-science professional who needs to better understand industry terminology, science, techniques and issues. Sponsored by: Veeva Systems Gartner research on short- and long-term strategies for IDMP compliance. | 
